Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.

Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD; New Approaches to Brain Tumor Therapy CNS Consortium.

Neuro Oncol. 2005 Jul;7(3):246-53.

2.

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.

Mikkelsen T, Lush R, Grossman SA, Carson KA, Fisher JD, Alavi JB, Rosenfeld S.

Invest New Drugs. 2007 Jun;25(3):259-63. Epub 2006 Nov 1.

3.

Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.

Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y.

Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1179-85.

PMID:
7961028
4.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA.

Neuro Oncol. 2007 Jan;9(1):29-38. Epub 2006 Nov 15.

5.
6.

Cutting copper curbs angiogenesis, studies show.

Vanchieri C.

J Natl Cancer Inst. 2000 Aug 2;92(15):1202-3. No abstract available.

PMID:
10922401
7.

Radiotherapy for glioblastoma in the elderly.

Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists.

N Engl J Med. 2007 Apr 12;356(15):1527-35.

8.

Survival trends in elderly patients with glioblastoma multiforme: resective surgery, radiation, and chemotherapy.

Patwardhan RV, Shorter C, Willis BK, Reddy P, Smith D, Caldito GC, Nanda A.

Surg Neurol. 2004 Sep;62(3):207-13; discussion 214-5.

PMID:
15336860
9.

Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.

Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S.

Cancer Chemother Pharmacol. 1998;42(2):118-26.

PMID:
9654111
10.

[The effect of extent of tumor resection on the outcome of combined therapy in patients with glioblastoma multiforme].

Jeremić B, Grulicić D, Samardzić M, Antunović V, Joksimović M, Djurić Lj, Milicić B, Nikolić N.

Srp Arh Celok Lek. 1997 Mar-Apr;125(3-4):93-8. Serbian.

PMID:
9221525
11.

Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021.

Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP.

Neuro Oncol. 2006 Jan;8(1):47-52.

12.
13.

Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.

Ford JM, Seiferheld W, Alger JR, Wu G, Endicott TJ, Mehta M, Curran W, Phan SC.

Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):831-8. Epub 2007 Jun 8.

PMID:
17560737
14.

A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy.

Salmaggi A, Riva M, Silvani A, Merli R, Tomei G, Lorusso L, Russo A, Marchioni E, Imbesi F; Lombardia Neuro-oncology Group.

Neurol Sci. 2005 Oct;26(4):227-34.

PMID:
16193249
15.

Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.

Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A.

J Neurooncol. 2011 Jun;103(2):317-24. doi: 10.1007/s11060-010-0389-0. Epub 2010 Sep 16.

16.

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR.

Clin Cancer Res. 2000 Oct;6(10):3878-84.

17.

Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.

Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK; Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):818-24. Epub 2006 Aug 2.

PMID:
16887285
18.

Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.

Muragaki Y, Maruyama T, Iseki H, Tanaka M, Shinohara C, Takakura K, Tsuboi K, Yamamoto T, Matsumura A, Matsutani M, Karasawa K, Shimada K, Yamaguchi N, Nakazato Y, Sato K, Uemae Y, Ohno T, Okada Y, Hori T.

J Neurosurg. 2011 Aug;115(2):248-55. doi: 10.3171/2011.4.JNS10377. Epub 2011 May 13. Erratum in: J Neurosurg. 2013 Mar;118(3):709.

PMID:
21568657
19.

Urinary copper excretion before and after oral intake of d-penicillamine in parents of patients with Wilson's disease.

Vieira J, Oliveira PV, Juliano Y, Warde KR, Deguti MM, Barbosa ER, Carrilho FJ, Cancado EL.

Dig Liver Dis. 2012 Apr;44(4):323-7. doi: 10.1016/j.dld.2011.11.001. Epub 2011 Dec 9.

PMID:
22169274
20.

Supplemental Content

Support Center